<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02016235</url>
  </required_header>
  <id_info>
    <org_study_id>13-004774</org_study_id>
    <nct_id>NCT02016235</nct_id>
  </id_info>
  <brief_title>Role Of Phosphorus And FGF 23 In Patients With Dent Disease</brief_title>
  <official_title>Role Of Phosphorus And FGF 23 In Patients With Dent Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with Dent disease have suppressed levels of FGF 23 which contributes to
      hypercalciuria, kidney stones, nephrocalcinosis and renal failure. Supplementation with
      phosphorus may reduce hypercalciuria.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">January 2019</completion_date>
  <primary_completion_date type="Actual">January 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Urine Total Protein</measure>
    <time_frame>baseline, day 7</time_frame>
    <description>Urine protein tests detect and/or measure protein being released into the urine. Normal urine protein elimination is less than 150 mg/day</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Dent Disease</condition>
  <arm_group>
    <arm_group_label>Dent Disease Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dent Disease subjects will receive 2 week supplementation with phosphorus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Kidney Stone subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Kidney stone with or without phosphate leak subjects will receive 2 week supplementation with phosphorus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dent Disease Observation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dent disease subjects will not get phosphorus</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phosphorus Supplement</intervention_name>
    <description>250 mg po qid</description>
    <arm_group_label>Dent Disease Intervention</arm_group_label>
    <arm_group_label>Kidney Stone subjects</arm_group_label>
    <other_name>K-phos neutral</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observation</intervention_name>
    <description>Baseline blood and urine measurements only</description>
    <arm_group_label>Dent Disease Observation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients will be recruited from those in the RKSC Dent Registry

          1. Diagnostic criteria for Dent disease Observational arm include:

               1. &lt;18 years old

               2. LMWP (at least 5 times above the upper limit of normal) and at least 1 of the
                  following criteria: 1. Hypercalciuria, 2. Kidney stones, 3. Nephrocalcinosis, 4.
                  Hypophosphatemia, 5. Renal phosphate leak, 6. Aminoaciduria, 7. Glucosuria
                  without diabetes mellitus, 8. Hematuria, 9. Renal insufficiency, 10. Family
                  history with x-linked inheritance or

               3. 1 of the above criteria (1-9) and confirmed genetic mutation of CLCN5 or OCRL1.

          2. Diagnostic criteria for Dent disease Intervention arm include:

               1. &gt;18 years old

               2. LMWP (at least 5 times above the upper limit of normal) and at least 1 of the
                  following criteria: 1. Hypercalciuria, 2. Kidney stones, 3. Nephrocalcinosis, 4.
                  Hypophosphatemia, 5. Renal phosphate leak, 6. Aminoaciduria, 7. Glucosuria
                  without diabetes mellitus, 8. Hematuria, 9. Renal insufficiency, 10. Family
                  history with x-linked inheritance or

               3. 1 of the above criteria (1-9) and confirmed genetic mutation of CLCN5 or OCRL1.

          3. Idiopathic calcium nephrolithiasis with renal phosphate leak

               1. Male patients &gt; 18 years old

               2. History of symptomatic calcium oxalate or calcium phosphate stone, hypercalciuria
                  (&gt;250 mg/24 hrs), renal phosphate leak (TMP/GFR &lt;2.07 mg/dl)

          4. Idiopathic calcium nephrolithiasis without renal phosphate leak

               1. Male patients &gt; 18 years old

               2. History of symptomatic calcium oxalate or calcium phosphate stone, hypercalciuria
                  (&gt;250 mg/24 hrs), renal phosphate leak (TMP/GFR &lt;2.07 mg/dl)

        Exclusion Criteria:

          1. Exclusion for Dent disease include: primary or secondary hyperparathyroidism,
             hyperthyroidism, chronic diarrhea states; intake of thiazide diuretics,
             glucocorticoids, or estrogens within one month of the study.

          2. Exclusion criteria for calcium stone formers include: primary or secondary
             hyperparathyroidism, hyperthyroidism, estimated GFR &lt;40 ml/mn/1.73m2, chronic diarrhea
             states; intake of thiazide diuretics, glucocorticoids, or estrogens within one month
             of the study.

          3. Exclusion criteria include history of symptomatic or asymptomatic kidney stone
             disease; primary or secondary hyperparathyroidism; estimated GFR &lt;40 ml/min/1.73m2,
             chronic diarrhea states; intake of thiazide diuretics, glucocorticoids, or estrogens
             within one month of the study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John C Lieske, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials.</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>December 6, 2013</study_first_submitted>
  <study_first_submitted_qc>December 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2013</study_first_posted>
  <results_first_submitted>December 30, 2019</results_first_submitted>
  <results_first_submitted_qc>March 19, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 23, 2020</results_first_posted>
  <last_update_submitted>March 19, 2020</last_update_submitted>
  <last_update_submitted_qc>March 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>John Lieske</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>Dent</keyword>
  <keyword>Dents</keyword>
  <keyword>Dent Disease</keyword>
  <keyword>Phosphorus Supplements</keyword>
  <keyword>FGF 23</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dent Disease</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 15, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/35/NCT02016235/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dent Disease Intervention</title>
          <description>Dent Disease subjects will receive 2 week supplementation with phosphorus
Phosphorus Supplement: 250 mg po qid</description>
        </group>
        <group group_id="P2">
          <title>Kidney Stone Subjects</title>
          <description>Kidney stone with or without phosphate leak subjects will receive 2 week supplementation with phosphorus
Phosphorus Supplement: 250 mg po qid</description>
        </group>
        <group group_id="P3">
          <title>Dent Disease Observation</title>
          <description>Dent disease subjects will not get phosphorus
Observation: Baseline blood and urine measurements only</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dent Disease Intervention</title>
          <description>Dent Disease subjects will receive 2 week supplementation with phosphorus
Phosphorus Supplement: 250 mg po qid</description>
        </group>
        <group group_id="B2">
          <title>Kidney Stone Subjects</title>
          <description>Kidney stone with or without phosphate leak subjects will receive 2 week supplementation with phosphorus
Phosphorus Supplement: 250 mg po qid</description>
        </group>
        <group group_id="B3">
          <title>Dent Disease Observation</title>
          <description>Dent disease subjects will not get phosphorus
Observation: Baseline blood and urine measurements only</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="10"/>
                    <count group_id="B4" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.4" spread="12.0"/>
                    <measurement group_id="B2" value="55.3" spread="14.6"/>
                    <measurement group_id="B3" value="10.2" spread="1.3"/>
                    <measurement group_id="B4" value="30.6" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="10"/>
                    <count group_id="B4" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="10"/>
                    <count group_id="B4" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Urine Total Protein</title>
        <description>Urine protein tests detect and/or measure protein being released into the urine. Normal urine protein elimination is less than 150 mg/day</description>
        <time_frame>baseline, day 7</time_frame>
        <population>Data were not collected for the Disease Dent Observation Group</population>
        <group_list>
          <group group_id="O1">
            <title>Dent Disease Intervention</title>
            <description>Dent Disease subjects will receive 2 week supplementation with phosphorus
Phosphorus Supplement: 250 mg po qid</description>
          </group>
          <group group_id="O2">
            <title>Kidney Stone Subjects</title>
            <description>Kidney stone with or without phosphate leak subjects will receive 2 week supplementation with phosphorus
Phosphorus Supplement: 250 mg po qid</description>
          </group>
          <group group_id="O3">
            <title>Dent Disease Observation</title>
            <description>Dent disease subjects will not get phosphorus
Observation: Baseline blood and urine measurements only. Day 7 Urine total protein not obtained</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Urine Total Protein</title>
          <description>Urine protein tests detect and/or measure protein being released into the urine. Normal urine protein elimination is less than 150 mg/day</description>
          <population>Data were not collected for the Disease Dent Observation Group</population>
          <units>mg/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1681" spread="979"/>
                    <measurement group_id="O2" value="59" spread="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events were collected over a period of 7 days for each subjects</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Dent Disease Intervention</title>
          <description>Dent Disease subjects will receive 2 week supplementation with phosphorus
Phosphorus Supplement: 250 mg po qid</description>
        </group>
        <group group_id="E2">
          <title>Kidney Stone Subjects</title>
          <description>Kidney stone with or without phosphate leak subjects will receive 2 week supplementation with phosphorus
Phosphorus Supplement: 250 mg po qid</description>
        </group>
        <group group_id="E3">
          <title>Dent Disease Observation</title>
          <description>Dent disease subjects will not get phosphorus
Observation: Baseline blood and urine measurements only. Day 7 Urine total protein not obtained</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John C. Lieske, M.D.</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-266-7960</phone>
      <email>Lieske.John@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

